Testing a new immunotherapy with chemo-radiation for limited-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing whether adding the immunotherapy drug serplulimab to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. It is for those who have not had any previous treatment for their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with limited-stage small cell lung cancer (stage II or III).
- You have not received any prior cancer treatments like chemotherapy, radiation, or immunotherapy.
- You are in good general health (able to care for yourself, with a performance status of 0 or 1).
- You have at least one tumor that can be measured by scans.
- You agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new combination of two immunotherapy drugs (adebrelimab and vunakizumab) plus chemotherapy for people with previously untreated extensive-stage small cell lung cancer. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation for people with limited-stage small cell lung cancer. After the initial treatment, adebrelimab is continued alone to help prevent the cancer from coming back.
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
This trial combines standard chemotherapy and radiation with two immunotherapy drugs (immune checkpoint inhibitors) to see if they work better together for people with limited-stage small cell lung cancer. It aims to improve outcomes without using strong immune-suppressing medicines.
This trial tests whether adding an immunotherapy drug (Serplulimab) to chemotherapy before surgery can help people with advanced stage III non-small cell lung cancer that cannot be removed. It aims to shrink the tumor and improve outcomes.
This trial tests a treatment plan that combines a short course of radiation with chemotherapy and an immunotherapy drug (adebrelimab). It is for people with limited-stage small cell lung cancer who haven't had treatment yet.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.